Barclays
NPCE icon

Barclays’s Neuropace NPCE Stock Holding History

Barclays’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Sell
34,845
-33,710
-49% -$506K ﹤0.01% 3238
2025
Q4 		$1.06M Buy
68,555
+3,560
+5% +$47.6K ﹤0.01% 3393
2025
Q3 		$670K Sell
64,995
-6,677
-9% -$63K ﹤0.01% 3617
2025
Q2 		$798K Buy
71,672
+40,508
+130% +$507K ﹤0.01% 3491
2025
Q1 		$383K Buy
31,164
+3,555
+13% +$44.5K ﹤0.01% 3691
2024
Q4 		$309K Buy
27,609
+6,976
+34% +$60.7K ﹤0.01% 4104
2024
Q3 		$144K Buy
20,633
+16,007
+346% +$117K ﹤0.01% 4461
2024
Q2 		$35K Sell
4,626
-9,244
-67% -$93.3K ﹤0.01% 4325
2024
Q1 		$183K Sell
13,870
-101
-0.7% -$1.44K ﹤0.01% 4162
2023
Q4 		$144K Buy
13,971
+3,132
+29% +$25K ﹤0.01% 4538
2023
Q3 		$105K Buy
10,839
+10,721
+9,086% +$62.8K ﹤0.01% 3585
2023
Q2 		$530 Hold
118
– – ﹤0.01% 4386
2023
Q1 		$548 Hold
118
– – ﹤0.01% 4949
2022
Q4 		$176 Sell
118
-3,100
-96% -$6.89K ﹤0.01% 5188
2022
Q3 		$12K Sell
3,218
-183
-5% -$882 ﹤0.01% 4237
2022
Q2 		$17K Sell
3,401
-1,152
-25% -$7.61K ﹤0.01% 4462
2022
Q1 		$38K Buy
+4,553
New +$39.3K ﹤0.01% 4225

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Barclays's NPCE Position: Q1 2026 in Review

Barclays reduced its Neuropace (NPCE) stake by 49% in Q1 2026, selling an estimated $506K and leaving 34,845 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Barclays first reported a position in NPCE in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.06M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Barclays held 34,845 shares of Neuropace worth $458K as of Q1 2026.
  • Barclays sold 33,710 Neuropace shares in Q1 2026, an estimated $506K.
  • Neuropace made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3238 holding.
  • Barclays first reported a position in Neuropace in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Neuropace position peaked at $1.06M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.